Premium
Communicating suffering in primary stage head and neck cancer *
Author(s) -
MOORE R.J.,
CHAMBERLAIN R.M.,
KHURI F.R.
Publication year - 2004
Publication title -
european journal of cancer care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 67
eISSN - 1365-2354
pISSN - 0961-5423
DOI - 10.1111/j.1365-2354.2004.00444.x
Subject(s) - medicine , fatalism , quality of life (healthcare) , qualitative research , disease , cancer , head and neck cancer , stage (stratigraphy) , nursing , paleontology , social science , philosophy , theology , sociology , biology
The findings presented in this discussion seek to make a contribution to quality of life (QOL) research, by highlighting the import of factors affecting the communication of primary stage head and neck cancer patient's experiences of suffering after treatments by their clinicians. Qualitative research methodology based on open‐ended interviews with 18 survivors of American Joint Committee on Cancer (AJCC) Stage I and Stage II, squamous cell carcinoma of the head and neck (SCCHN) were used. The interviews were transcribed verbatim and thematically analysed. In this preliminary analysis, three important themes emerged: (1) a self diminished by cancer; (2) the fear of addiction to pain medications; and (3) hopelessness and the loss of meaning in life after SCCHN. Our present findings indicate that SCCHN patients understand their experiences of cancer and under‐report their experiences of suffering mainly because of fear. These include fears of: being further diminished by SCCHN, fears of addiction, and an inability to cope with the additional losses associated with SCCHN. As a consequence, and perhaps, because of a failure the part of clinicians and patients to adequately address these fears, SCCHN patients may also experience greater psychological morbidity, becoming fatalistic about biomedicine's ability to restore them to health after cancer, or related symptoms, including pain, despite being ‘cured.’ This study provides a perspective on why this under‐reporting occurs, thereby potentially enhancing clinician–patient communication and the QOL of SCCHN patients who present with curable disease.